EXFORGE HCT Drug Patent Profile

Which patents cover Exforge Hct, and what generic alternatives are available?

Exforge Hct is a drug marketed by Novartis and is included in one NDA.

The generic ingredient in EXFORGE HCT is amlodipine besylate; hydrochlorothiazide; valsartan. There are fifty drug master file entries for this compound. Five suppliers are listed for this compound. Additional details are available on the amlodipine besylate; hydrochlorothiazide; valsartan profile page.

Summary for EXFORGE HCT

US Patents:	0
Applicants:	1
NDAs:	1
Finished Product Suppliers / Packagers:	1
Clinical Trials:	15
Patent Applications:	10
Drug Prices:	Drug price information for EXFORGE HCT
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for EXFORGE HCT
What excipients (inactive ingredients) are in EXFORGE HCT?	EXFORGE HCT excipients list
DailyMed Link:	EXFORGE HCT at DailyMed

See drug prices for EXFORGE HCT

Recent Clinical Trials for EXFORGE HCT

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
International Bio service	Phase 1
Novartis Pharmaceuticals	Phase 4
Hanlim Pharm. Co., Ltd.	Phase 1

See all EXFORGE HCT clinical trials

Pharmacology for EXFORGE HCT

Drug Class	Angiotensin 2 Receptor Blocker Calcium Channel Blocker Dihydropyridine Calcium Channel Blocker Thiazide Diuretic
Mechanism of Action	Angiotensin 2 Receptor Antagonists Calcium Channel Antagonists Cytochrome P450 3A Inhibitors
Physiological Effect	Increased Diuresis

Paragraph IV (Patent) Challenges for EXFORGE HCT

Tradename	Dosage	Ingredient	Strength	NDA	ANDAs Submitted	Submissiondate
EXFORGE HCT	Tablets	amlodipine besylate; hydrochlorothiazide; valsartan	10 mg/12.5 mg/ 160 mg	022314	1	2009-10-22
EXFORGE HCT	Tablets	amlodipine besylate; hydrochlorothiazide; valsartan	5 mg/12.5 mg/160 mg, 5 mg/25 mg/160 mg, 10 mg/25 mg/160 mg and 10 mg/25 mg/320 mg	022314	1	2009-09-14

US Patents and Regulatory Information for EXFORGE HCT

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Novartis	EXFORGE HCT	amlodipine besylate; hydrochlorothiazide; valsartan	TABLET;ORAL	022314-001	Apr 30, 2009	AB	RX	Yes	No
Novartis	EXFORGE HCT	amlodipine besylate; hydrochlorothiazide; valsartan	TABLET;ORAL	022314-004	Apr 30, 2009	AB	RX	Yes	No
Novartis	EXFORGE HCT	amlodipine besylate; hydrochlorothiazide; valsartan	TABLET;ORAL	022314-002	Apr 30, 2009	AB	RX	Yes	No
Novartis	EXFORGE HCT	amlodipine besylate; hydrochlorothiazide; valsartan	TABLET;ORAL	022314-003	Apr 30, 2009	AB	RX	Yes	No
Novartis	EXFORGE HCT	amlodipine besylate; hydrochlorothiazide; valsartan	TABLET;ORAL	022314-005	Apr 30, 2009	AB	RX	Yes	Yes

Expired US Patents for EXFORGE HCT

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Novartis	EXFORGE HCT	amlodipine besylate; hydrochlorothiazide; valsartan	TABLET;ORAL	022314-004	Apr 30, 2009	8,101,599
Novartis	EXFORGE HCT	amlodipine besylate; hydrochlorothiazide; valsartan	TABLET;ORAL	022314-001	Apr 30, 2009	8,101,599
Novartis	EXFORGE HCT	amlodipine besylate; hydrochlorothiazide; valsartan	TABLET;ORAL	022314-003	Apr 30, 2009	8,101,599
Novartis	EXFORGE HCT	amlodipine besylate; hydrochlorothiazide; valsartan	TABLET;ORAL	022314-005	Apr 30, 2009	8,101,599
Novartis	EXFORGE HCT	amlodipine besylate; hydrochlorothiazide; valsartan	TABLET;ORAL	022314-002	Apr 30, 2009	8,101,599

International Patents for EXFORGE HCT

When does loss-of-exclusivity occur for EXFORGE HCT?

Based on analysis by DrugPatentWatch, the following patents block generic entry in the countries listed below:

Argentina

Australia

Brazil

Canada

Chile

China

Ecuador

European Patent Office

Hong Kong

Japan

Mexico

Morocco

New Zealand

Norway

Peru

Russian Federation

South Africa

South Korea

Taiwan

Tunisia

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

See the table below for additional patents covering EXFORGE HCT around the world.

Country	Patent Number	Title	Estimated Expiration
Austria	134624
Australia	644844
Australia	7115191
Canada	2036427	COMPOSES ACYLES (ACYL COMPOUNDS)
Canada	2232775	COMPOSES ACYLES (ACYL COMPOUNDS)

Supplementary Protection Certificates for EXFORGE HCT

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
0443983	91347	Luxembourg		91347, EXPIRES: 20160212
0443983	C00443983/02	Switzerland		PRODUCT NAME: VALSARTAN UND AMLODIPIN; REGISTRATION NUMBER/DATE: SWISSMEDIC 57771 22.12.2006
0443983	C300445	Netherlands		PRODUCT NAME: VALSARTAN, AMLODIPINE EN HYDROCHLOORTHIAZIDE EN FARMACEUTISCH AANVAARDBARE ZOUTEN DAARVAN; REGISTRATION NO/DATE: EU/1/09/569/001-060 20091016
0443983	CA 2010 00014	Denmark
0443983	91676	Luxembourg		91676, EXPIRES: 20160212

EXFORGE HCT Market Dynamics and Financial Trajectory: Pricing, Share, Exclusivity, and Generic/Biosimilar Risk

Last updated: June 7, 2026

EXFORGE HCT (valsartan/amlodipine hydrochloride) has limited near-term growth upside in most markets because its demand is tied to a mature antihypertensive category and ongoing generic erosion. Financial trajectory is driven by (1) baseline hypertension volume, (2) substitution away from branded fixed-dose combinations toward generics and fewer-pill regimens, and (3) payer formulary position that typically deteriorates as price pressure increases post-brand-to-generic transition.

What is EXFORGE HCT and why does its market dynamics look “mature” instead of growth-oriented?

EXFORGE HCT is a fixed-dose combination antihypertensive containing:

• Valsartan (ARB)
• Amlodipine (CCB)
• Hydrochlorothiazide (thiazide diuretic)

Core demand drivers

• Treating uncontrolled hypertension when dual therapy is insufficient (ARB + CCB, or ARB + thiazide, or CCB + thiazide) and clinicians move patients to triple therapy.
• Long chronic treatment cycles with prescription renewal behavior that can stabilize volume even as pricing declines.

Category forces

• Hypertension drugs are high volume and heavily genericized in the U.S. and most large ex-U.S. markets.
• Fixed-dose combinations can defend share longer than single agents, but they still face replacement when generics match the exact dose combinations or when prescribers switch to equivalent dual-then-add-on strategies.

What typically changes the trajectory

• Payer step therapy tightening (preferred agents, prior authorization).
• Negative gross-to-net due to higher rebate pressure for branded products.
• Loss of formulary status in commercial plans once lower-priced equivalents dominate.

How does EXFORGE HCT pricing and gross-to-net pressure evolve after branded penetration peaks?

U.S. pricing dynamic (generalizable to this class)

• Branded antihypertensives in older molecules face accelerating rebate pressure once multiple generic competitors enter.
• Net price trends track formulary placement and rebate intensity more than list price.

Implications for financial trajectory

• Revenue tends to fall faster than unit volume once rebate and discounting intensify.
• Fixed-dose combinations can sustain unit share slightly longer because prescribers and patients prefer fewer tablets per day, but the unit decline still tends to follow generic penetration.

When do generics typically displace EXFORGE HCT and what does that mean for revenue timing?

For an older fixed-dose combination, the revenue pattern usually follows:

1. Launch/uptake phase: growing prescriptions and payer adoption.
2. Plateau: stable volume as combination therapy becomes standard for some uncontrolled patients.
3. Price compression: as generic versions of components and then the fixed-dose combinations gain traction.
4. Acceleration in revenue decline: when the exact-dose combination is available as low-cost equivalents and payer coverage shifts.

Key market mechanism

• Even if some branded strength remains in specific subpopulations, overall revenue is constrained by:
  • generic pricing arbitrage
  • plan formulary substitution
  • patient copay sensitivity
  • pharmacy switch behavior

What patents protect EXFORGE HCT and how do they shape market exclusivity and generic entry risk?

EXFORGE HCT is a combination product built from known actives (valsartan, amlodipine, hydrochlorothiazide). For market-exclusivity analysis, the commercial question is not whether the active ingredients were novel, but whether the specific fixed-dose combinations, dosing regimens, crystalline forms, compositions, or manufacturing methods for the product had enforceable protection and remaining regulatory exclusivity when challengers entered.

How this affects financial trajectory

• If the U.S. and major ex-U.S. markets reached the point where generic substitution is available at the same dose strengths, branded revenue usually shifts into a structural decline rather than a cyclical slowdown.

What is the Orange Book status of EXFORGE HCT, and does it matter for revenue more than list price?

The Orange Book is relevant because it identifies:

• Approved drug product entries
• Patent codes tied to marketing exclusivity and listed patents
• Expiration and potential Paragraph IV exposure

Why it matters financially

• Patent loss creates “entry certainty” for generic manufacturers and converts competitive pressure into a predictable revenue step-down.
• Even when the brand retains volume, margin collapses due to rebate changes to fight switch and maintain pharmacy access.

How many patents cover EXFORGE HCT combinations and which patent families tend to drive litigation risk?

In fixed-dose antihypertensive combinations, the highest litigation risk often clusters around:

• compositions/formulations (including fixed-dose tablets and specific ratios)
• manufacturing processes for the combination drug product
• method-of-use claims if any exist beyond basic hypertension treatment
• specific dosage strength claims tied to commercial product lines

Financial linkage

• Strong, unexpired product-specific patent coverage can delay generic entry and sustain net sales.
• Once combination-specific patents expire, brand pricing leverage usually erodes quickly.

What patent litigation affects EXFORGE HCT and how does it impact launch calendars?

Generic launch calendars often depend on:

• Paragraph IV certifications against Orange Book patents
• court outcomes or settlement dates
• triggers tied to expiration of listed patents or regulatory exclusivity

Revenue impact mechanism

• Settlement terms can create a “stay” period, delaying branded revenue compression.
• Court rulings can shorten the timeline and accelerate generic substitution.

What generic entry risks exist for EXFORGE HCT by dose strength and label?

Fixed-dose combination brands typically face risk that is strength-specific because generic manufacturers can target:

• most-prescribed strengths first
• strengths with easiest manufacturing scale-up
• strengths with fewer form/formulation barriers

Financial trajectory effect

• Partial strength substitution can pressure blended net revenue before full label displacement.
• Once the major strengths are available generically, branded share erodes rapidly.

How does EXFORGE HCT compare with competing triple-therapy antihypertensive options?

Competitive substitution risk is driven by how payers and prescribers view:

• fixed-dose vs loose combination dosing
• tablet burden and adherence advantages
• preferred ARB/CCB/thiazide combinations by plan
• cost-effectiveness in formulary models

Typical competitor sets

• Triple-therapy fixed-dose combinations using other ARBs
• Dual therapy regimens with add-on thiazide where plan preferences differ
• Generic versions of the component drugs that are used as substitutes for fixed-dose therapy

What this means for market dynamics

• Even if EXFORGE HCT retains clinical familiarity, branded revenue growth is constrained once cheaper alternatives are on-formulary.

What is the likely revenue trajectory for EXFORGE HCT across the next 3–5 years?

Given the maturity of hypertension fixed-dose combinations and typical U.S. branded-to-generic patterns for older combination products, the expected trajectory is:

• Continued decline in net sales driven by generic substitution
• Low likelihood of meaningful market expansion unless a rare payer-driven reason maintains branded exclusivity or a unique formulation advantage persists
• Margin pressure as the brand uses rebates to defend shelf position

Business implication

• For portfolio planning, EXFORGE HCT is more likely to be managed as a cash-flowing legacy asset rather than an R&D-backed growth platform.

Which geographies typically matter most for EXFORGE HCT commercial performance?

Financial exposure depends on where combination fixed-dose prescribing is high and where generics are slower or faster:

• U.S.: strong generic penetration drives pricing compression and share erosion once barriers fall.
• EU/UK: similar structure with local pricing and reimbursement policies that accelerate switch after patent/exclusivity expiration.
• Canada/Australia: often follow predictable generic timelines; payer controls can intensify displacement.
• Emerging markets: may show longer tail if regulatory, pricing controls, or market structure delays generic competition, but usually with less absolute revenue.

Result

• The overall financial trajectory is usually anchored by the U.S. because it sets the most competitive pressure benchmark.

How do manufacturing and supply factors influence EXFORGE HCT financial resilience?

Fixed-dose tablets can be vulnerable to:

• raw material pricing (for hydrochlorothiazide and pharmaceutical-grade intermediates)
• cost of maintaining bioequivalence-grade manufacturing quality across multiple strengths
• supply constraints that temporarily cap volume even when demand exists

Financial linkage

• In mature products, supply issues translate into lost units quickly because prescribers can switch to alternative strengths or equivalent generic combinations.

Key Takeaways

• EXFORGE HCT’s market dynamics are structurally “mature” because it is a fixed-dose combination of widely available antihypertensive actives and faces ongoing substitution risk from generics.
• Financial trajectory is expected to be dominated by gross-to-net compression and formulary-driven switching rather than unit growth.
• Patent and Orange Book status determine generic entry timing, which typically turns revenue decline into a stepwise erosion once major dose strengths become available at low cost.
• Competitive pressure comes from fixed-dose and component-based triple-therapy strategies that payers steer toward lower-cost equivalents.
• Near-term commercial upside is limited unless a product-specific defensible differentiation delays combination substitution on key strengths.

FAQs

1. How does payer formulary status most affect EXFORGE HCT net sales over time?
   By increasing rebate intensity and driving pharmacy switching once generic fixed-dose equivalents or strong component substitutes are preferred.

2. What factors determine which EXFORGE HCT dose strengths lose exclusivity first?
   Generic manufacturing feasibility, bioequivalence pathways, and which strengths are most emphasized in payer utilization.

3. Do fixed-dose combinations like EXFORGE HCT defend market share longer than single agents?
   Sometimes on units, but revenues typically decline faster once exact-dose generics enter and net pricing deteriorates.

4. How do Paragraph IV challenges typically translate into branded revenue impact?
   They can delay or accelerate generic launch calendars; settlements often postpone entry, while adverse rulings can trigger faster revenue compression.

5. What is the main commercial risk to EXFORGE HCT outside patent expiration?
   Formulary and rebate strategy that shifts coverage to cheaper alternatives even before full competition becomes available across all strengths.